Not well-established; estimated hours based on thymosin beta-4 data
SKUs
2
Evidence
Preliminary
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a protein the body produces naturally and releases when tissue is damaged. Thymosin Beta-4 is found in nearly every type of cell and plays a central role in how the body organises repair after injury — helping cells migrate into the wound site, reducing excessive scarring, and stimulating new blood vessel growth. TB-500 retains those healing properties in a smaller, more stable form. It has been extensively studied in preclinical models and veterinary medicine, and is notable for having the most advanced human trial data of the peptides commonly researched for tissue repair — cardiac research has reached phase 2 human trials.
Wound Healing Research
TB-500 and Thymosin Beta-4 have been studied in multiple wound healing contexts. Research shows acceleration of wound closure, improved angiogenesis at the wound site, and reduced scarring. Equine veterinary applications represent a substantial part of the evidence base.
Cardiac Protection Research
Of all the tissue-healing applications researchers have studied, the cardiac work on Thymosin Beta-4 is the most clinically advanced. Phase 2 human trials have been initiated to examine whether TB-500 can reduce cell death and support regeneration of heart muscle after a heart attack — an outcome that animal studies consistently support. This makes it one of the few repair-focused peptides with any human trial data at all.
Neurological Research
Thymosin Beta-4 has been studied for neurological recovery following traumatic brain injury and spinal cord injury in animal models, showing reductions in neuronal death and improvements in functional recovery.
Musculoskeletal Recovery
TB-500 is studied for tendon, ligament, and muscle healing in both animal models and informal human research contexts. It is one of the most commonly researched compounds for sports-related tissue injuries.
Accelerates wound healing in multiple animal and veterinary studies.
Cardiac protection after myocardial infarction in preclinical models, with phase 2 trials initiated.
Neurological recovery improvements in animal models of brain and spinal injury.
Strong equine veterinary evidence base for soft tissue injury treatment.
No completed formal human clinical trials for musculoskeletal or wound healing indications.
TB-500 does not have completed human clinical trials for the tissue healing applications it is most commonly researched for. The cardiac trials represent the most advanced clinical research. The equine veterinary evidence, while extensive, does not substitute for human clinical trial data. It is not FDA-approved. Informal human use reports are not a substitute for clinical trial evidence.
Thymosin Beta-4 is found in every type of cell in the body and serves as a reservoir for actin — the protein that gives cells their shape and allows them to move. When tissue is damaged, Thymosin Beta-4 is released and helps neighboring cells migrate into the wound site to begin repair. It promotes the formation of new blood vessels to supply the repair area, modulates the inflammatory response to prevent excessive scarring, and activates stem cell-like precursor cells that can differentiate into needed repair cells. TB-500 is the portion of Thymosin Beta-4 that retains most of this biological activity in a smaller, more stable molecule.
TB-500 has not been evaluated in formal human safety trials for healing applications. Animal studies have not shown concerning toxicity. Reports from people who have used it outside of clinical trials describe it as generally well-tolerated, though this kind of uncontrolled observation is not a substitute for proper safety evaluation. It is not FDA-approved. Research-grade purity and sterility standards are important practical considerations for any research use.
Preliminary
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Published Research Ranges
2–10mg weekly in published research protocols
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Thymosin Beta-4 Promotes Repair of Injured Skeletal Muscle and Peripheral Nerves
Annals of the New York Academy of Sciences • 2012
• DOI: 10.1111/j.1749-6632.2012.06576.x
Effects of Malnutrition on the Immune System and Infection and the Role of Nutritional Strategies Regarding Improvements in Children's Health Status: A Literature Review
Advances in Regenerative Stem Cell Therapy in Androgenic Alopecia and Hair Loss: Wnt pathway, Growth-Factor, and Mesenchymal Stem Cell Signaling Impact Analysis on Cell Growth and Hair Follicle Development
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.